Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season

The United Kingdom is introducing a universal annual influenza vaccination programme for children. Live attenuated influenza vaccine (LAIV) effectiveness (VE) against laboratory-confirmed influenza hospitalisation in 2 to 6 year-olds in England was measured in 2015/16 using the screening method. VE...

Descripción completa

Detalles Bibliográficos
Autores principales: Pebody, Richard, Sile, Bersabeh, Warburton, Fiona, Sinnathamby, Mary, Tsang, Camille, Zhao, Hongxin, Ellis, Joanna, Andrews, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2017
Materias:
Surveillance and Outbreak Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388092/
https://www.ncbi.nlm.nih.gov/pubmed/28182539
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.4.30450
Descripción
Sumario:The United Kingdom is introducing a universal annual influenza vaccination programme for children. Live attenuated influenza vaccine (LAIV) effectiveness (VE) against laboratory-confirmed influenza hospitalisation in 2 to 6 year-olds in England was measured in 2015/16 using the screening method. VE adjusted for age, geography and month was 54.5% (95% confidence interval (CI): 31.5% to 68.4%) for all influenza types combined; 48.3% (95% CI: 16.9% to 67.8%) for A(H1N1)pdm09 and 70.6% (95% CI: 33.2% to 87.1%) for B. The findings support on-going programme roll-out.

Ejemplares similares